Patents Examined by Carlos Azpuru
  • Chitosan acrylic acid derivative hemostatic powder
    Patent number: 10946039
    Abstract: The present invention provides a hemostatic powder. The hemostatic powder is mainly present in the form of a columnar particle, wherein the ratio of axial length to diameter of the columnar particle is less than 5; the hemostatic powder includes a polymer represented by the following structural formula: wherein the R is at least one selected from the group consisting of —NH2, —OCH2CH2OH, —OCH2CH2CH2OH, —OH, —ONa, —OK and —OCa; m, n and p respectively represent number percentages of corresponding repeating units in polymer molecules, and satisfy the following equations: m+n+p=1, p/(m+n+p)=0.05˜0.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: March 16, 2021
    Assignees: Jiangsu NewValue Medical Products Co., Ltd., Shnaghai Newvalue Medical Products Co., Ltd.
    Inventors: Yingshan Zhou, Rui Jiang, Zuguang Gong, Liqin Xu, Shiming Zhou, Xiaoming Zhou
  • Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability
    Patent number: 10940155
    Abstract: A quetiapine fumarate composition for oral administration is provided comprising a pharmaceutically acceptable salt or solvate of quetiapine existing as a suspension in an aqueous carrier agent. The inventive liquid formulation demonstrates high bioavailability consistent with approved dosage forms, low agglomeration, reduced content of excipients commonly used in solid oral dosage forms and extended shelf life stability. Also provided is a method of manufacturing a liquid quetiapine suspension composition for oral administration and methods of administering therapeutically effective dosages of an oral liquid quetiapine suspension composition to patients in need thereof.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: March 9, 2021
    Assignee: TLC Therapeutics, LLC
    Inventors: Carl Tierney, Andrew Gardner, Jan Pick-Katolik, Stacey Powell, Mark Foley, Laurence Ramsey, Andrew Hardeman
  • Injectable suspension comprising 3-beta-hydroxy-5-alpha-pregnan-20-one, and a method for the manufacturing thereof
    Patent number: 10933014
    Abstract: The present invention relates to aseptic suspensions, physically stable and injectable through a 25G needle or thinner, comprising crystalline, non-micronized 3-beta-hydroxy-5-alpha-pregnan-20-one particles, a mixture of acylglycerols and cholesterol, processes for preparing crystalline, non-micronized, 3-beta-hydroxy-5-alpha-pregnan-20-one suitable for such suspensions, as well as methods for manufacturing such suspensions.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: March 2, 2021
    Assignee: ASARINA PHARMA AB
    Inventors: Magnus Brisander, Karol Horvath, Björn Norrlind
  • Flowable bulk granular alpa-glucan
    Patent number: 10934418
    Abstract: Disclosed herein are compositions comprising polysaccharide particles with an average size of about 0.1-10 mm. These particles comprise at least (i) about 50%-90% by weight water or an aqueous solution, and (ii) about 10%-50% by weight insoluble alpha-glucan, or an insoluble cationic ether thereof, comprising alpha-1,3-glycosidic linkages and having a weight-average degree of polymerization (DPw) of at least about 100. Further disclosed are methods of preparing these compositions, as well as systems for storing and/or moving them.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: March 2, 2021
    Assignee: DUPONT INDUSTRIAL BIOSCIENCES USA, LLC
    Inventors: Timothy Allan Bell, Dean M. Fake, Scott M. Herkimer, Dhiren V. Patel, Tyler D. Pritchett
  • Drug-eluting surgical articles with a plurality of geometric elements
    Patent number: 10926005
    Abstract: Disclosed herein is a biomaterial for treating a condition. A biomaterial of the disclosure can be, for example, a surgical article. The biomaterial can comprise a plurality of geometric elements and a therapeutic agent. The biomaterial can comprise a first geometric element formed by a porous border that comprises a polymer and the therapeutic agent. The biomaterial can comprise a second geometric element formed by a non-porous border and a solid region, wherein the therapeutic agent may not diffuse into the second geometric element. Implantation of a biomaterial disclosed herein into a subject can treat, for example, cancer.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: February 23, 2021
    Assignee: BioSapien Inc.
    Inventor: Khatija Pinky Ali
  • Methods for forming implants from injected thermoreversible gels
    Patent number: 10918611
    Abstract: A method of forming an implant in a tissue can include: providing an injectable liquid composition comprising one or more precursors of a crosslinkable composition; injecting the injectable composition into the tissue at the rate of about 10-12000 injections per minute and/or at an amount of 1.0E-02 ml to 1.0E-16 ml per injection; and crosslinking the one or more precursors of the crosslinkable composition so as to form a crosslinked composition.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: February 16, 2021
    Assignee: PATHAK HOLDINGS LLC
    Inventor: Chandrashekhar P. Pathak
  • Device and kit for dosing and dispensing non-liquid medicine
    Patent number: 10918636
    Abstract: A kit comprising a device for dosing and dispensing a dose of a non-liquid medicine that is readily dispersible in an aqueous solution suitable for oral administration, preferably a temozolomide formulation that can be titrated readily and accurately.
    Type: Grant
    Filed: March 16, 2019
    Date of Patent: February 16, 2021
    Assignee: AMPLIPHARM PHARMACEUTICALS, LLC
    Inventors: Gary Payton, Jeff Bryant, Frank Francavilla
  • Injectable aqueous implant formulation containing ascorbic acid
    Patent number: 10918592
    Abstract: An injectable aqueous implant formulation, and processes for making and using the formulation, wherein the injectable aqueous implant formulation has been sterilized by gamma-ray or X-ray-irradiation and can be extruded through a tapering system and an 18 gauge (0.838 mm inner diameter) 25.4 mm long cannula with a force not exceeding 60 N, which comprises 25-45 w/w % of a mixture of nanocrystalline hydroxyapatite particles derived from natural bone having a size of 50 to 200 ?m as determined by sieving and fragments of naturally crosslinked fibrous collagen material that pass through a 0.5 mm sieve, whereby the w/w ratio of nanocrystalline hydroxyapatite to collagen is from 1.8 to 4.5, which contains at least 0.05% (w/w) ascorbic acid.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: February 16, 2021
    Assignee: Geistlich Pharma AG
    Inventors: Daniel Suppiger, Paul Buxton, Nino Kurz
  • Nanoformulations containing encapsulted omega-3 fatty acids
    Patent number: 10912326
    Abstract: Disclosed is a method for making and using insoluble, biodegradable, nanoparticles containing the omega-3 fatty acids EPA and DHA in selected ratios. Tests show a surprising effect that the nanoformulation is twice as potent and at least five times more sustained leading to at least tenfold (2×5) higher bioavailability at equal dose (1% v/v).
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: February 9, 2021
    Inventors: Rachelle MacSweeney, George Jackowski, Paul Kerth
  • Zeinmersome nanocarriers for drug delivery to the liver
    Patent number: 10905651
    Abstract: Zeinmersomes (ZMS) comprising zein, a phospholipid and a PEG-polymer are formulated to encapsulate a drug of interest. Olmesartan medoxomil (OM) is encapsulated in the ZMS (OM-ZMS) for oral administration and taken up by the liver where OM diffuses from the ZMS nanocarrier. OM concentrations in liver were at least 8 times higher than that measured in plasma. Established fibrosis was reversed in a thioacetamide-induced rat model of human chronic hepatic fibrosis. The OM-ZMS provides a hepatic drug delivery system that reduces the potential of side-effects caused by OM, including OM-associated sprue-like enteropathy, to treat chronic hepatic fibrosis and associated duodenal changes.
    Type: Grant
    Filed: July 31, 2020
    Date of Patent: February 2, 2021
    Assignee: King Abdulaziz University
    Inventors: Hussam Aly Sayed Murad, Osama Abdelhakim Aly Ahmed, Usama Ahmed Fahmy Ahmed
  • Colorless material with improved antimicrobial performance
    Patent number: 10897907
    Abstract: Aspects of this disclosure pertain to a colorless material that includes a carrier, copper-containing particles, and quaternary ammonium. In one or more embodiments, the material exhibits, in the CIE L*a*b* system, an L* value in the range from about 91 to about 100, and a C* value of less than about 7, wherein C* equals ?(a*2+b*2). In some embodiments, the material exhibits a greater than 3 log reduction in a concentration of Staphylococcus aureus, under the EPA Test Method for Efficacy of Copper Alloy as a Sanitizer testing conditions.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: January 26, 2021
    Assignee: CORNING INCORPORATED
    Inventors: Joydeep Lahiri, Florence Christine Monique Verrier
  • Amorphous silicon oxide, amorphous silicon oxynitride, and amorphous silicon nitride thin films and uses thereof
    Patent number: 10898618
    Abstract: Amorphous SiOx (SiO2), SiONx, silicon nitride (Si3N4), surface treatments are provided, on both metal (titanium) and non-metal surfaces. Amorphous silicon-film surface treatments are shown to enhance osteoblast and osteoblast progenitor cell bioactivity, including biomineral formation and osteogenic gene panel expression, as well as enhanced surface hydroxyapatite (HA) formation. A mineralized tissue interface is provided using the amorphous silicon-based surface treatments in the presence of osteoblasts, and provides improved bone cell generation/repair and improved interface for secure attachment/bonding to bone. Methods for providing PEVCD-based silicon overlays onto surfaces are provided. Methods of increasing antioxidant enzyme (e.g., superoxide dismutase) expression at a treated surface for enhanced healing are also provided.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: January 26, 2021
    Assignees: THE TEXAS A&M UNIVERSITY SYSTEM, BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM, UT-BATTELLE, LLC
    Inventors: Venu Varanasi, Pranesh Aswath, Megen Maginot, Nickolay V. Lavrick
  • Compositions and methods for inhibiting the biological activity of soluble biomolecules
    Patent number: 10888602
    Abstract: The disclosure provides, among other things, compositions that bind to and inhibit the biological activity of soluble biomolecules, as well as pharmaceutical compositions thereof. Also provided herein are a number of applications (e.g., therapeutic applications) in which the compositions are useful.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: January 12, 2021
    Assignee: NaNotics, LLC
    Inventor: Louis Hawthorne
  • Cucurbituril suspension compositions
    Patent number: 10881592
    Abstract: Stable suspension compositions including cucurbiturils. More particularly, the stable suspension compositions including cucurbituril particles suspended in a medium. Also, the preparation of the suspension composition and a method of counteracting malodour including application of the suspension composition to a source of malodour.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: January 5, 2021
    Assignee: AQDOT LIMITED
    Inventors: Roger Coulston, David Diec, Andrew Michael Howe, Jose Martinez-Santiago
  • Biodegradable intravitreal tyrosine kinase implants
    Patent number: 10881608
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: January 5, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
  • Composition for providing room temperature long-term constant-concentration chlorine dioxide solution in aqueous medium and preparation method thereof
    Patent number: 10881111
    Abstract: The present invention provides a composition of long-term constant-concentration aqueous chlorine dioxide solution including dissolved chlorine dioxide, a decomposition inhibitor for dissolved chlorine dioxide, and a pH modifier, and a method for preparing the same.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: January 5, 2021
    Assignees: NEOCL Co., Ltd.
    Inventors: Yong Jun Kim, Jung Hyuck Cho
  • Passivated magnetic nanoparticles for cell targeting and methods of preparation and use
    Patent number: 10881740
    Abstract: A composition and methods of use and preparation are provided. The composition may comprise a magnetic nanoparticle comprising: a passivation layer; and at least one unique entity that is attached to the magnetic nanoparticle. For example, the composition may include a magnetic nanoparticle and an antibody attached to the magnetic nanoparticle. Such magnetic nanoparticle architecture can provide treatment by, and screening of, nanoparticles functionalized with various functional species.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: January 5, 2021
    Assignee: Verily Life Sciences LLC
    Inventors: Zhan Wang, Nicole Peck
  • Nasolacrimal drainage system implants for drug therapy
    Patent number: 10874606
    Abstract: An implant for insertion through a punctum and into a canalicular lumen of a patient. The implant includes a matrix of material, a therapeutic agent dispersed in the matrix of material, a sheath disposed over a portion of the matrix of material and configured to inhibit the therapeutic agent from being released from the matrix of material into the canalicular lumen and to allow the therapeutic agent to be released from a surface of the matrix of material to a tear film, and a retention structure configured to retain the implant within the canalicular lumen.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: December 29, 2020
    Assignee: Mati Therapeutics Inc.
    Inventors: Eugene de Juan, Jr., Stephen Boyd, Cary Reich, Alan Rapacki, Hanson S. Gifford, Mark Deem
  • Compositions and methods for treating damaged hair
    Patent number: 10874598
    Abstract: Compositions and methods are disclosed for repairing damaged keratin fibers or otherwise strengthening keratin fibers, including hair of the human scalp, and particularly hair that has been damaged chemically, physically, thermally or by other means. The compositions comprise 3,3?-thiodipropionic acid (TDPA) or a derivative thereof in a cosmetically acceptable vehicle.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: December 29, 2020
    Assignee: Avon Products, Inc.
    Inventors: Sen Yang, Allwyn Colaco, Michael J. Fair
  • Thrombin microcapsules, preparation and uses thereof
    Patent number: 10869912
    Abstract: Provided are spray-dried thrombin powders comprising microcapsules, methods of preparation and uses thereof.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: December 22, 2020
    Assignee: Omrix Biopharmaceuticals Ltd.
    Inventors: Erez Ilan, Assaf Gershonovitch, Rivka Kaufman